Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for migraine headache severity and frequency reduction
IRCT20260804070530N1Phase 3Recruiting
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Ketamine infusion with Placebo saline infusion (2 arms). Primary endpoints: Headache severity and Headache frequency. Started Aug 2026; status: recruiting.
02
Drugs
ketamine
03
Conditions
migraine
Beyond the preview
Go deeper on IRCT20260804070530N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260804070530N1.